To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Defense, Transportation.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H0BC0F039D70A45208D9DB266EF533A49: 1. Short title This Act may be cited as the Defense Production and Active Pharmaceutical Ingredients Act.
- Section HDF8F0E17AE9F4662BAE8D753B04036DA: 2. Modification of support for research and development of bioindustrial manufacturing processes Section 215(c)(1) of the James M. Inhofe National Defense...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
This bill, To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Defense, Transportation
Primary Purpose
This bill, To amend the National Defense Authorization Act for Fiscal Year 2023 to extend Federal support for bioindustrial manufacturing processes to include support for the manufacturing of certain pharmaceutical ingredients., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
Contextual inference, no direct clause citation- health care providers and patients
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- federal implementing agencies
- health care providers and patients
Contextual inference, no direct clause citation
Legislative Progress
IntroducedMs. Slotkin introduced the following bill; which was referred to …
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "federal_implementing_agencies"
- → Federal agencies assigned duties by the bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology